Similar articles for PMID: 25370334

Year	Number of Results
2009	1
2010	1
2011	1
2012	2
2013	2
2014	5
2015	2
2016	5
2017	4
2018	4
2019	2
2020	4
2021	3
2022	3
2024	0

1

Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy.

Hansen L, Iqbal N, Ekholm E, Cook W, Hirshberg B. Hansen L, et al. Endocr Pract. 2014 Nov;20(11):1187-97. doi: 10.4158/EP14489.OR. Endocr Pract. 2014. PMID: 25370334

2

Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.

Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N. Rosenstock J, et al. Diabetes Care. 2015 Mar;38(3):376-83. doi: 10.2337/dc14-1142. Epub 2014 Oct 28. Diabetes Care. 2015. PMID: 25352655 Clinical Trial.

3

Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.

Qin Y, Adams J, Solis-Herrera C, Triplitt C, DeFronzo R, Cersosimo E. Qin Y, et al. Diabetes Care. 2020 Oct;43(10):2519-2527. doi: 10.2337/dc19-1993. Epub 2020 Jul 21. Diabetes Care. 2020. PMID: 32694214 Free PMC article. Clinical Trial.

4

Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.

Vilsbøll T, Ekholm E, Johnsson E, Garcia-Sanchez R, Dronamraju N, Jabbour SA, Lind M. Vilsbøll T, et al. Diabetes Obes Metab. 2020 Jun;22(6):957-968. doi: 10.1111/dom.13981. Epub 2020 Feb 23. Diabetes Obes Metab. 2020. PMID: 32003150 Free PMC article. Clinical Trial.

5

Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.

Frias JP, Gonzalez-Galvez G, Johnsson E, Maaske J, Testa MA, Simonson DC, Dronamraju N, Garcia-Sanchez R, Peters AL. Frias JP, et al. Diabetes Obes Metab. 2020 Jul;22(7):1083-1093. doi: 10.1111/dom.13997. Epub 2020 Mar 9. Diabetes Obes Metab. 2020. PMID: 32052516 Free PMC article. Clinical Trial.

6

COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.

Ekholm E, Hansen L, Johnsson E, Iqbal N, Carlsson B, Chen H, Hirshberg B. Ekholm E, et al. Endocr Pract. 2017 Mar;23(3):258-265. doi: 10.4158/EP161323.OR. Epub 2016 Nov 16. Endocr Pract. 2017. PMID: 27849380 Clinical Trial.

7

Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.

Frías JP, Maaske J, Suchower L, Johansson L, Hockings PD, Iqbal N, Wilding JPH. Frías JP, et al. Diabetes Obes Metab. 2022 Jan;24(1):61-71. doi: 10.1111/dom.14548. Epub 2021 Sep 28. Diabetes Obes Metab. 2022. PMID: 34514692 Free PMC article. Clinical Trial.

8

Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.

Hu S, Deng X, Ma Y, Li Z, Wang Y, Wang Y. Hu S, et al. Appl Health Econ Health Policy. 2021 Jan;19(1):69-79. doi: 10.1007/s40258-020-00603-7. Appl Health Econ Health Policy. 2021. PMID: 32783086

9

Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.

Hermans MP, Delibasi T, Farmer I, Lohm L, Maheux P, Piatti P, Malvolti E, Jörgens S, Charbonnel B. Hermans MP, et al. Curr Med Res Opin. 2012 Oct;28(10):1635-45. doi: 10.1185/03007995.2012.735646. Epub 2012 Oct 12. Curr Med Res Opin. 2012. PMID: 23020253 Clinical Trial.

10

Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.

Elkind-Hirsch KE, Paterson MS, Seidemann EL, Gutowski HC. Elkind-Hirsch KE, et al. Fertil Steril. 2017 Jan;107(1):253-260.e1. doi: 10.1016/j.fertnstert.2016.09.023. Epub 2016 Oct 27. Fertil Steril. 2017. PMID: 28228317 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

31 results

Results by year